Oga Toru, Nishimura Koichi, Tsukino Mitsuhiro, Hajiro Takashi, Sato Susumu, Ikeda Akihiko, Hamada Chikuma, Mishima Michiaki
Respiratory Division, Kyoto-Katsura Hospital, Kyoto, Japan.
Ann Allergy Asthma Immunol. 2002 Dec;89(6):619-25. doi: 10.1016/S1081-1206(10)62111-4.
There are few long-term studies of the effects of treatment on the natural course of asthma.
To investigate the longitudinal changes in airflow limitation and airway hyperresponsiveness (AHR) in asthma.
We recruited 81 outpatients (never smokers) with stable asthma from the Kyoto University Hospital. They were evaluated for pulmonary function and AHR, expressed by forced expiratory volume in 1 second (FEV1) and the provocation dose that caused a 20% fall in FEV1 (PD20-FEV1), respectively, at entry and every 6 months over 3 years. We used random effects models to estimate the slopes of these changes, and then evaluated the relationship between these changes and their predictive factors.
Using random effects models, the percentage of the predicted FEV1 (%FEV1) declined significantly but slightly at a mean rate of 0.5%/year (P = 0.002; 95% confidence interval, 0.3 to 0.8). The mean decline rate of FEV1 was 34 mL/year. However, Log(PD20-FEV1) showed significant improvement at a mean rate of 0.088 cumulative units/year (P < 0.001; 95% confidence interval, 0.053 to 0.122). Multiple regression analysis showed that the baseline values of %FEV1 and Log(PD20-FEV1) were the most significant predictive factors for their subsequent changes, respectively.
In stable asthmatic patients treated according to international guidelines, airflow limitation progressed at a nearly normal rate over 3 years. However, AHR continued to improve despite its ceiling effects. Multiple regression analysis revealed a significant negative relationship between the initial values and the subsequent changes in airflow limitation and AHR, respectively.
关于治疗对哮喘自然病程影响的长期研究较少。
研究哮喘患者气流受限和气道高反应性(AHR)的纵向变化。
我们从京都大学医院招募了81名稳定期哮喘门诊患者(从不吸烟者)。在入组时以及3年中每6个月对他们进行肺功能和AHR评估,分别用第1秒用力呼气容积(FEV1)和导致FEV1下降20%的激发剂量(PD20-FEV1)来表示。我们使用随机效应模型估计这些变化的斜率,然后评估这些变化与其预测因素之间的关系。
使用随机效应模型,预测FEV1百分比(%FEV1)显著但轻微下降,平均每年下降0.5%(P = 0.002;95%置信区间,0.3至0.8)。FEV1的平均下降率为每年34 mL。然而,Log(PD20-FEV1)以每年0.088累积单位的平均速率显著改善(P < 0.001;95%置信区间,0.053至0.122)。多元回归分析表明,%FEV1和Log(PD20-FEV1)的基线值分别是其后续变化的最显著预测因素。
在按照国际指南治疗的稳定期哮喘患者中,气流受限在3年中以接近正常的速率进展。然而,尽管存在天花板效应,AHR仍持续改善。多元回归分析显示,气流受限和AHR的初始值与后续变化之间分别存在显著的负相关关系。